UBS Group AG Has $4.44 Million Stake in Collegium Pharmaceutical, Inc. $COLL

UBS Group AG decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 62.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 95,887 shares of the specialty pharmaceutical company’s stock after selling 159,572 shares during the quarter. UBS Group AG’s holdings in Collegium Pharmaceutical were worth $4,440,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after acquiring an additional 825 shares in the last quarter. Millennium Management LLC raised its stake in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares in the last quarter. Jane Street Group LLC raised its stake in Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after acquiring an additional 90,255 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock valued at $2,131,000 after buying an additional 2,592 shares during the period.

Analyst Ratings Changes

Several research analysts have recently issued reports on COLL shares. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $34.07 on Friday. The business has a 50 day moving average of $34.26 and a 200-day moving average of $41.54. Collegium Pharmaceutical, Inc. has a 1 year low of $28.34 and a 1 year high of $50.79. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The company has a market capitalization of $1.10 billion, a P/E ratio of 16.70 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.49 earnings per share. On average, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This represents a 41.05% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.